Side-by-side · Research reference

DSIPvsGHRP-2

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 2Reviewed15/42 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

DSIP

GHRP-2

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Feedback intact?

—

Yes, with somatostatin feedback active

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

DSIP

GHRP-2

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

100–300 mcg per injectionBowers 1990

Frequency

Once daily, pre-sleep

1–3× per day

Lower / starter dose

50 mcg pre-sleep

50 mcg per dose

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Phase 2 + clinical diagnostic useBowers 1990

Duration

8–12 weeks per cycle

8–12 weeks on / 4 off (anecdotal)

Reconstitution

Bacteriostatic water

Timing

30–60 min pre-sleep

Pre-sleep + fasted preferred

Half-life

Short plasma; CNS effects last hours

~30 minMalagón 1999

04Side Effects & Safety

Parameter

DSIP

GHRP-2

Injection site reaction

Mild irritation

Mild erythema

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

Cortisol elevation

—

Mild but measurableBowers 1990

Prolactin elevation

—

Mild but measurable

Hunger

—

Strong appetite increase

IGF-1 elevation

—

Strong; monitor with chronic high-dose use

Cancer risk

—

Contraindicated in active malignancy

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

GHRP-2

·Untreated diabetes

05Administration Protocol

Parameter

DSIP

GHRP-2

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Injection site

SQ — abdomen. Rotate sites.

SQ — abdomen or thigh. Rotate sites.

3. Timing

30–60 min pre-sleep.

Pre-sleep + fasted preferred.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

29–31G insulin syringe.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

DSIP

— no documented stacks

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006